New Chimeric Antigen Receptor Design for Solid Tumors
In recent years, chimeric antigen receptor (CAR) T-cell therapy has become popular in immunotherapy, particularly after its tremendous success in the treatment of lineage-restricted hematologic cancers. However, the application of CAR T-cell therapy for solid tumors has not reached its full potentia...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2017-12-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fimmu.2017.01934/full |
id |
doaj-a6fffad037cc455f888f9f4806725d06 |
---|---|
record_format |
Article |
spelling |
doaj-a6fffad037cc455f888f9f4806725d062020-11-24T22:38:45ZengFrontiers Media S.A.Frontiers in Immunology1664-32242017-12-01810.3389/fimmu.2017.01934306985New Chimeric Antigen Receptor Design for Solid TumorsYuedi Wang0Yuedi Wang1Feifei Luo2Feifei Luo3Jiao Yang4Jiao Yang5Chujun Zhao6Yiwei Chu7Yiwei Chu8Department of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, ChinaBiotherapy Research Center, Fudan University, Shanghai, ChinaBiotherapy Research Center, Fudan University, Shanghai, ChinaDepartment of Digestive Diseases, Huashan Hospital, Fudan University, Shanghai, ChinaDepartment of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, ChinaBiotherapy Research Center, Fudan University, Shanghai, ChinaNorthfield Mount Hermon School, Mount Hermon, MA, United StatesDepartment of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, ChinaBiotherapy Research Center, Fudan University, Shanghai, ChinaIn recent years, chimeric antigen receptor (CAR) T-cell therapy has become popular in immunotherapy, particularly after its tremendous success in the treatment of lineage-restricted hematologic cancers. However, the application of CAR T-cell therapy for solid tumors has not reached its full potential because of the lack of specific tumor antigens and inhibitory factors in suppressive tumor microenvironment (TME) (e.g., programmed death ligand-1, myeloid-derived suppressor cells, and transforming growth factor-β). In this review, we include some limitations in CAR design, such as tumor heterogeneity, indefinite spatial distance between CAR T-cell and its target cell, and suppressive TME. We also summarize some new approaches to overcome these hurdles, including targeting neoantigens and/or multiple antigens at once and depleting some inhibitory factors.http://journal.frontiersin.org/article/10.3389/fimmu.2017.01934/fullchimeric antigen receptor T-cellimmunotherapysolid tumoradoptive T-cell therapytumor microenvironment |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yuedi Wang Yuedi Wang Feifei Luo Feifei Luo Jiao Yang Jiao Yang Chujun Zhao Yiwei Chu Yiwei Chu |
spellingShingle |
Yuedi Wang Yuedi Wang Feifei Luo Feifei Luo Jiao Yang Jiao Yang Chujun Zhao Yiwei Chu Yiwei Chu New Chimeric Antigen Receptor Design for Solid Tumors Frontiers in Immunology chimeric antigen receptor T-cell immunotherapy solid tumor adoptive T-cell therapy tumor microenvironment |
author_facet |
Yuedi Wang Yuedi Wang Feifei Luo Feifei Luo Jiao Yang Jiao Yang Chujun Zhao Yiwei Chu Yiwei Chu |
author_sort |
Yuedi Wang |
title |
New Chimeric Antigen Receptor Design for Solid Tumors |
title_short |
New Chimeric Antigen Receptor Design for Solid Tumors |
title_full |
New Chimeric Antigen Receptor Design for Solid Tumors |
title_fullStr |
New Chimeric Antigen Receptor Design for Solid Tumors |
title_full_unstemmed |
New Chimeric Antigen Receptor Design for Solid Tumors |
title_sort |
new chimeric antigen receptor design for solid tumors |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Immunology |
issn |
1664-3224 |
publishDate |
2017-12-01 |
description |
In recent years, chimeric antigen receptor (CAR) T-cell therapy has become popular in immunotherapy, particularly after its tremendous success in the treatment of lineage-restricted hematologic cancers. However, the application of CAR T-cell therapy for solid tumors has not reached its full potential because of the lack of specific tumor antigens and inhibitory factors in suppressive tumor microenvironment (TME) (e.g., programmed death ligand-1, myeloid-derived suppressor cells, and transforming growth factor-β). In this review, we include some limitations in CAR design, such as tumor heterogeneity, indefinite spatial distance between CAR T-cell and its target cell, and suppressive TME. We also summarize some new approaches to overcome these hurdles, including targeting neoantigens and/or multiple antigens at once and depleting some inhibitory factors. |
topic |
chimeric antigen receptor T-cell immunotherapy solid tumor adoptive T-cell therapy tumor microenvironment |
url |
http://journal.frontiersin.org/article/10.3389/fimmu.2017.01934/full |
work_keys_str_mv |
AT yuediwang newchimericantigenreceptordesignforsolidtumors AT yuediwang newchimericantigenreceptordesignforsolidtumors AT feifeiluo newchimericantigenreceptordesignforsolidtumors AT feifeiluo newchimericantigenreceptordesignforsolidtumors AT jiaoyang newchimericantigenreceptordesignforsolidtumors AT jiaoyang newchimericantigenreceptordesignforsolidtumors AT chujunzhao newchimericantigenreceptordesignforsolidtumors AT yiweichu newchimericantigenreceptordesignforsolidtumors AT yiweichu newchimericantigenreceptordesignforsolidtumors |
_version_ |
1725712071683735552 |